{"id":1068055,"date":"2021-12-21T01:45:51","date_gmt":"2021-12-21T06:45:51","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/kinnate-biopharma-inc-to-present-updates-from-its-lead-raf-and-fgfr-inhibitor-candidate-programs-at-upcoming-scientific-meetings\/"},"modified":"2024-08-18T11:42:23","modified_gmt":"2024-08-18T15:42:23","slug":"kinnate-biopharma-inc-to-present-updates-from-its-lead-raf-and-fgfr-inhibitor-candidate-programs-at-upcoming-scientific-meetings","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/kinnate-biopharma-inc-to-present-updates-from-its-lead-raf-and-fgfr-inhibitor-candidate-programs-at-upcoming-scientific-meetings.php","title":{"rendered":"Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs\u00a0at Upcoming Scientific Meetings"},"content":{"rendered":"<p><![CDATA[AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors]]><\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/12\/20\/2355652\/0\/en\/Kinnate-Biopharma-Inc-to-Present-Updates-from-its-Lead-RAF-and-FGFR-Inhibitor-Candidate-Programs-at-Upcoming-Scientific-Meetings.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs\u00a0at Upcoming Scientific Meetings\">Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs\u00a0at Upcoming Scientific Meetings<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to see the original: Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs\u00a0at Upcoming Scientific Meetings <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/kinnate-biopharma-inc-to-present-updates-from-its-lead-raf-and-fgfr-inhibitor-candidate-programs-at-upcoming-scientific-meetings.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068055","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068055"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068055"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068055\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}